135 related articles for article (PubMed ID: 20414937)
21. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells.
Zhong J; Gencay MM; Bubendorf L; Burgess JK; Parson H; Robinson BW; Tamm M; Black JL; Roth M
J Cell Physiol; 2006 May; 207(2):540-52. PubMed ID: 16447244
[TBL] [Abstract][Full Text] [Related]
22. Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer.
Yoshimoto A; Kasahara K; Nishio M; Hourai T; Sone T; Kimura H; Fujimura M; Nakao S
Jpn J Clin Oncol; 2005 May; 35(5):233-8. PubMed ID: 15886272
[TBL] [Abstract][Full Text] [Related]
23. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
[TBL] [Abstract][Full Text] [Related]
24. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
27. Treatment options for stage I nonseminoma.
Feldman DR
J Clin Oncol; 2014 Dec; 32(34):3797-800. PubMed ID: 25366681
[No Abstract] [Full Text] [Related]
28. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
29. Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by basic fibroblast growth factor and dexamethasone in periodontal ligament cells.
Hakki SS; Hakki EE; Nohutcu RM
J Periodontal Res; 2009 Dec; 44(6):794-802. PubMed ID: 19602122
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
Cianfrocca M; Cooley TP; Lee JY; Rudek MA; Scadden DT; Ratner L; Pluda JM; Figg WD; Krown SE; Dezube BJ
J Clin Oncol; 2002 Jan; 20(1):153-9. PubMed ID: 11773164
[TBL] [Abstract][Full Text] [Related]
31. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
[TBL] [Abstract][Full Text] [Related]
32. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers.
Mwaura B; Mahendran B; Hynes N; Defreitas D; Avalos G; Adegbola T; Adham M; Connolly CE; Sultan S
Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):306-10. PubMed ID: 16169261
[TBL] [Abstract][Full Text] [Related]
33. Expression of vascular endothelial factor-A, gelatinases (MMP-2, MMP-9) and TIMP-1 in uterine leiomyomas.
Korompelis P; Piperi C; Adamopoulos C; Dalagiorgou G; Korkolopoulou P; Sepsa A; Antsaklis A; Papavassiliou AG
Clin Chem Lab Med; 2015 Aug; 53(9):1415-24. PubMed ID: 25470608
[TBL] [Abstract][Full Text] [Related]
34. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
[TBL] [Abstract][Full Text] [Related]
36. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease.
Fukuda S; Shirahama T; Imazono Y; Tsushima T; Ohmori H; Kayajima T; Take S; Nishiyama K; Yonezawa S; Akiba S; Akiyama S; Ohi Y
Cancer; 1999 Mar; 85(6):1323-30. PubMed ID: 10189138
[TBL] [Abstract][Full Text] [Related]
37. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
38. Effect of High Intensity Interval Training on Matrix Metalloproteinases in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy.
Lee K; Kang I; Mack WJ; Mortimer J; Sattler F; Salem G; Dieli-Conwright CM
Sci Rep; 2020 Apr; 10(1):5839. PubMed ID: 32246106
[TBL] [Abstract][Full Text] [Related]
39. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Ferretti G; Fabi A; Carlini P; Papaldo P; Cordiali Fei P; Di Cosimo S; Salesi N; Giannarelli D; Alimonti A; Di Cocco B; D'Agosto G; Bordignon V; Trento E; Cognetti F
Oncology; 2005; 69(1):35-43. PubMed ID: 16088233
[TBL] [Abstract][Full Text] [Related]
40. Effects of basic fibroblast factor (bFGF) on MMP-2, TIMP-2, and type-I collagen levels in human lung carcinoma fibroblasts.
Nakoman C; Resmi H; Ay O; Acikel U; Atabey N; Güner G
Biochimie; 2005; 87(3-4):343-51. PubMed ID: 15781321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
